Drug intelligence / Profile preview

AP40

Development stage: Preclinical
Lead developer: Aprogen
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

AP40, developed by Aprogen Inc., is an Fc Fragment drug currently in preclinical development. It functions as an inhibitor of Carbonic Anhydrase 12 (CA12). This mechanism of action is being investigated for its potential therapeutic applications in various neoplasms and skin and musculoskeletal diseases, with a specific focus on Triple Negative Breast Cancer.

Targets

CA12 (Carbonic anhydrase XII)

Beyond the preview

Go deeper on AP40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP40.

Explore the full profile